Company profile: Akouos
1.1 - Company Overview
Company description
- Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
Products and services
- Gene Therapy Platform: Architects AAV vector-based system to restore and preserve hearing in genetically-defined patients across causes from single mutations to ototoxic drug exposure and aging processes
- AK-OTOF: Engineers single-administration gene therapy targeting sensorineural hearing loss due to otoferlin mutations, aiming to restore hearing
- Resonate Program: Delivers auditory-neuropathy-specific genetic testing and optional counseling for individuals, at no cost to them or their insurance.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akouos
Exicure
HQ: United States
Website
- Description: Provider of a new class of immunomodulatory and gene silencing drugs against validated targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exicure company profile →
Elsie Biotechnologies
HQ: United States
Website
- Description: Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elsie Biotechnologies company profile →
DNA Therapeutics
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development as a privately held company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Therapeutics company profile →
Spark Therapeutics
HQ: United States
Website
- Description: Provider of potentially curative, one-time gene therapy treatments for genetic diseases, including investigational programs such as SPK-8011 for hemophilia A, fidanacogene elaparvovec (SPK-9001) for hemophilia B, SPK-3006 for Pompe disease, and gene therapies targeting Stargardt and Huntington’s diseases, plus AAV-based research programs for the retina, liver, and central nervous system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spark Therapeutics company profile →
Nanogenics
HQ: United Kingdom
Website
- Description: Provider of research-based biotechnology developing artificial viruses for gene therapy. Products include LipTide, a synthetic peptide nanoparticle that mimics natural viruses for targeted RNA delivery to various cell types with low toxicity and repeat dosing, and ECP-105, a glaucoma therapy enhancing trabeculectomy by increasing bleb survival and reducing scarring with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanogenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akouos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akouos
2.2 - Growth funds investing in similar companies to Akouos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akouos
4.2 - Public trading comparable groups for Akouos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →